[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

September 2016, Vol 2, No. 9, Pages 1113-1244

Original Investigation

Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1137-1145. doi:10.1001/jamaoncol.2016.0732

This observational study with prospectively collected data examines a cohort of 3408 men and women with stage I to III colorectal cancer (CRC) to evaluate the association of body mass index at the time of and following CRC diagnosis with risk of mortality.

Association of Physical Activity by Type and Intensity With Digestive System Cancer Risk

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1146-1153. doi:10.1001/jamaoncol.2016.0740

This cohort study examines the association between physical activity and digestive system cancer risk, accounting for amount, type (aerobic vs resistance), and intensity of physical activity.

Preventable Incidence and Mortality of Carcinoma Associated With Lifestyle Factors Among White Adults in the United States

Abstract Full Text
free access has active quiz has audio
JAMA Oncol. 2016;2(9):1154-1161. doi:10.1001/jamaoncol.2016.0843

This study analyzes data from 2 large US cohorts and the US white population to evaluate the association of lifestyle factors with cancer incidence and mortality.

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1162-1169. doi:10.1001/jamaoncol.2016.2314

This secondary analysis of a randomized clinical trial investigates whether molecular subtypes of colon cancer are associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy.

Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1170-1176. doi:10.1001/jamaoncol.2016.0685

This multisite cohort study of 685 women younger than 70 years with nonmetastatic invasive breast cancer explores whether complementary and alternative medicine use is associated with decreased breast cancer chemotherapy initiation.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2016;2(9):1179-1186. doi:10.1001/jamaoncol.2016.0775

This subgroup analysis of a randomized clinical trial evaluates the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond first progression of metastatic renal cell carcinoma.

Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1188-1196. doi:10.1001/jamaoncol.2016.0483

This nationwide matched cohort study in a Swedish population and health registers examines the relative risks of several mental disorders during the periods before and after cancer diagnosis compared with individuals without cancer.

Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1197-1206. doi:10.1001/jamaoncol.2016.0605

This prospective cohort analysis evaluates the association between intake of marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer characterized by immune infiltrate.

Research Letter

Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1236-1238. doi:10.1001/jamaoncol.2016.1143

This study uses data from the US National Cancer Data Base to examine the adoption of androgen deprivation therapy vs dose-escalated radiotherapy for prostate cancer across the United States.

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1238-1240. doi:10.1001/jamaoncol.2016.0931

This study assesses the number of cancer therapies approved by the US Food and Drug Administration that achieved the clinically meaningful improvements suggested by the American Society of Clinical Oncology.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1240-1242. doi:10.1001/jamaoncol.2016.1304

This case series describes biopsy-proven treatment-induced resistance mutations acquired by patients with non–small-cell lung cancer and EGFR mutations treated with erlotinib.

Review

Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review

Abstract Full Text
JAMA Oncol. 2016;2(9):1209-1216. doi:10.1001/jamaoncol.2016.0585

This systematic review analyzes advanced pancreatic adenocarcinoma phase 3 clinical trials performed over the past 25 years.

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review

Abstract Full Text
JAMA Oncol. 2016;2(9):1217-1222. doi:10.1001/jamaoncol.2016.0639

This review summarizes available and candidate biomarkers for the selection of patients who might benefit from the use of PD-1/PD-L1 inhibitors for the treatment of non–small-cell lung cancer.

Viewpoint

Technology Spotlight

3-Dimensional Printed Anatomic Models as Planning Aids in Complex Oncology Surgery

Abstract Full Text
JAMA Oncol. 2016;2(9):1121-1122. doi:10.1001/jamaoncol.2016.2469

This Viewpoint examines the results of a survey of 19 tumor surgeons regarding their experiences with oncologic 3-D models; surgeons were asked how helpful the models were or how likely the models were to improve care.

Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?

Abstract Full Text
JAMA Oncol. 2016;2(9):1123-1124. doi:10.1001/jamaoncol.2016.1288

This Viewpoint questions the necessity of frequent cardiovascular monitoring for patients receiving trastuzumab therapy and proposes that intense monitoring be reserved for patients with risk factors shown to be associated with congestive heart failure.

Measuring the Value of New Medications and Implications for Medicare’s Proposed Part B Drug Payment Model

Abstract Full Text
JAMA Oncol. 2016;2(9):1125-1126. doi:10.1001/jamaoncol.2016.2037

This Viewpoint uses Medicare's 2016 Proposed Part B Drug Payment Model to discuss alternative drug payment models that would align drug costs with value, keep drugs affordable while rewarding innovation, and incorporate patient values and preferences.

From the JAMA Network

NSAIDs and EGFR Inhibitors for Duodenal Polyp Prevention

Abstract Full Text
JAMA Oncol. 2016;2(9):1223-1225. doi:10.1001/jamaoncol.2016.1227

This commentary discusses a study published in JAMA that evaluated the effect of a combination of sulindac and erlotinib on duodenal adenoma regression in patients with familial adenomatous polyposis.

Editorial

The Obesity Paradox and Mortality After Colorectal Cancer: A Causal Conundrum

Abstract Full Text
JAMA Oncol. 2016;2(9):1127-1129. doi:10.1001/jamaoncol.2016.0868

Physical Activity and Digestive System Cancer Risk: Still Chasing the Promise

Abstract Full Text
JAMA Oncol. 2016;2(9):1129-1131. doi:10.1001/jamaoncol.2016.1035

The Preventability of Cancer: Stacking the Deck

Abstract Full Text
JAMA Oncol. 2016;2(9):1131-1133. doi:10.1001/jamaoncol.2016.0889

Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine

Abstract Full Text
JAMA Oncol. 2016;2(9):1133-1134. doi:10.1001/jamaoncol.2016.2304
Invited Commentary

Complementary and Alternative Medicine Use Among Patients With Cancer: A Challenge in the Oncologist-Patient Relationship

Abstract Full Text
JAMA Oncol. 2016;2(9):1177-1178. doi:10.1001/jamaoncol.2016.0713

Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?

Abstract Full Text
JAMA Oncol. 2016;2(9):1186-1187. doi:10.1001/jamaoncol.2016.0876
Comment & Response

Self-Responsibility for Our Good Health—Reply

Abstract Full Text
JAMA Oncol. 2016;2(9):1242-1243. doi:10.1001/jamaoncol.2016.3074

Self-responsibility for Our Good Health

Abstract Full Text
JAMA Oncol. 2016;2(9):1242. doi:10.1001/jamaoncol.2016.3079

Intended Target of the Centers for Disease Control and Prevention Opioid Guidelines—Reply

Abstract Full Text
JAMA Oncol. 2016;2(9):1243-1244. doi:10.1001/jamaoncol.2016.2184

Intended Target of the Centers for Disease Control and Prevention Opioid Guidelines

Abstract Full Text
JAMA Oncol. 2016;2(9):1243. doi:10.1001/jamaoncol.2016.2185
Correction

Error in Figures and Table

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1244. doi:10.1001/jamaoncol.2016.1942

Error in Figure 2 Axis Labels

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1244. doi:10.1001/jamaoncol.2016.2968

Error in Figure Legends

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1244. doi:10.1001/jamaoncol.2016.3537
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1114. doi:10.1001/jamaoncol.2015.3534
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(9):1113. doi:10.1001/jamaoncol.2015.3533
×